Oncology Transactions and the 340B Drug Pricing Program

Area of Science:

• Health Economics
• Healthcare Management
• Pharmaceutical Policy

Background:

• The 340B Drug Pricing Program is a U.S. federal program created to reduce the cost of outpatient drugs for certain safety-net healthcare providers.
• Covered entities participating in the 340B program are eligible for significant discounts on outpatient prescription drugs.
• Expansion to new locations is a strategic goal for many covered entities to increase patient reach and service offerings.

Purpose of the Study:

• To summarize the operational framework of the 340B program.
• To identify and describe business models facilitating geographic expansion for 340B participating entities.
• To analyze the implications of these business models for healthcare access and financial sustainability.

Main Methods:

• Literature review of existing 340B program guidelines and analyses.
• Case study analysis of successful expansion strategies employed by covered entities.
• Qualitative assessment of various business models, including contract pharmacy arrangements and partnerships.

Main Results:

• Several viable business models exist for 340B covered entities to expand their services to new sites.
• These models often involve strategic partnerships, leveraging contract pharmacies, and careful financial planning.
• Successful expansion can lead to increased patient access to discounted medications and improved community health outcomes.

Conclusions:

• The 340B program offers opportunities for covered entities to strategically grow their service footprint.
• Understanding and implementing appropriate business models is crucial for successful expansion and maximizing program benefits.
• Expansion initiatives supported by the 340B program can significantly enhance healthcare accessibility in underserved areas.